Open Access. Powered by Scholars. Published by Universities.®
Social and Behavioral Sciences Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Social and Behavioral Sciences
Efficacy Of Galcanezumab For Migraine Prevention In Patients With A Medical History Of Anxiety And/Or Depression: A Post Hoc Analysis Of The Phase 3, Randomized, Double-Blind, Placebo-Controlled Regain, And Pooled Evolve-1 And Evolve-2 Studies, Todd A. Smitherman, Gretchen E. Tietjen, Kory Schuh, Vladimir Skljarevski, Sarah Lipsius, Deborah N. D’Souza, Eric M. Pearlman
Efficacy Of Galcanezumab For Migraine Prevention In Patients With A Medical History Of Anxiety And/Or Depression: A Post Hoc Analysis Of The Phase 3, Randomized, Double-Blind, Placebo-Controlled Regain, And Pooled Evolve-1 And Evolve-2 Studies, Todd A. Smitherman, Gretchen E. Tietjen, Kory Schuh, Vladimir Skljarevski, Sarah Lipsius, Deborah N. D’Souza, Eric M. Pearlman
Faculty and Student Publications
© 2020 Eli Lilly and Company. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC, on behalf of American Headache Society Objective: This post hoc analysis evaluated the efficacy of galcanezumab for the prevention of migraine in patients with and without comorbid anxiety and/or depression. Background: Patients with migraine have a higher risk of anxiety and/or depression. Given the high prevalence of psychiatric symptoms and their potential negative prognostic impact, determining the efficacy of migraine treatments in patients with these comorbidities is important. Methods: The results of 2 phase 3 episodic migraine studies of patients with …